J. Mason

发表

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia

M. Maris, S. Dakhil, F. Ravandi, 2014, British journal of haematology.

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

L. Gordon, M. Kaminski, J. Winter, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy.

M. Christian, M. Breslin, T. Shea, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Scalable Method for Molecular Network Reconstruction Identifies Properties of Targets and Mutations in Acute Myeloid Leukemia

G. Paternostro, C. Piermarocchi, K. Vuori, 2014, J. Comput. Biol..

Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.

P. Bierman, I. Flinn, C. Flowers, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reinfusion and serial measurements of carboplatin-mobilized peripheral-blood progenitor cells in patients receiving multiple cycles of high-dose chemotherapy.

M. Breslin, T. Shea, R. Taetle, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose carboplatin chemotherapy with GM-CSF and peripheral blood progenitor cell support: a model for delivering repeated cycles of dose-intensive therapy.

M. Breslin, T. Shea, A. Storniolo, 1993, Cancer treatment reviews.

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.

I. Lowy, R. Soiffer, E. Ball, 2009, Blood.

CTLA 4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

I. Lowy, R. Soiffer, E. Ball, 2009 .

A randomized phase II study of amifostine used as stem cell protectant in non-hodgkin lymphoma patients receiving cisplatin-based salvage chemotherapy prior to stem cell transplant.

M. Territo, J. Andrey, C. Emmanouilides, 2001, Journal of hematotherapy & stem cell research.

High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California.

J. Glaspy, L. Damon, D. Irwin, 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A dose-escalation study of carboplatin/cyclophosphamide/etoposide along with autologous bone marrow or peripheral blood stem cell rescue.

T. Shea, A. Storniolo, M. Green, 1992, Seminars in oncology.

An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant

L. Frakes, B. Meisenberg, J. Mason, 1997, Bone Marrow Transplantation.

Induction of molecular remission by donor peripheral blood leukocyte therapy in patients relapsing with extramedullary blastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation.

J. Wang-Rodriguez, A. Ho, A. Bashey, 1998, Oncology reports.

High-Dose Carboplatin with Peripheral Blood Stem Cell and Growth Factor Support

M. Breslin, T. Shea, A. Storniolo, 1991 .

A Scalable Method for Molecular Network Reconstruction Identifies Properties of Targets and Mutations in Acute Myeloid Leukemia

G. Paternostro, C. Piermarocchi, K. Vuori, 2014, J. Comput. Biol..

The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors

E. Ruppin, J. Lee, I. Jeremias, 2021, Nature Communications.

RNF5 Regulation of RBBP4 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors

E. Ruppin, K. Brown, J. Lee, 2020 .

Advances in autologous stem cell transplantation.

A. Ho, J. Mason, 1997, Cancer investigation.

Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation.

J. Radich, M. Loken, M. Flowers, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Intravascular lymphoma: a role for single-agent rituximab

L. Bazhenova, J. Mason, P. Higginbottom, 2006, Leukemia & lymphoma.

Long-term remission of myelofibrosis following nonmyeloablative allogeneic peripheral blood progenitor cell transplantation in older age: the Scripps Clinic experience

J. Andrey, J. Mason, W. Miller, 2004, Bone Marrow Transplantation.

Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs. a combination of both.

A. Ho, L. Terstappen, T. Lane, 1996, Experimental hematology.

Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR)

J. Armitage, R. Herzig, A. Bashey, 2001, Bone Marrow Transplantation.

Intramedullary PNET of the Spine: Long-term Survival After Combined Modality Therapy and Subsequent Relapse

J. Anson, J. Mason, J. Khoury, 2011, Journal of pediatric hematology/oncology.

Soluble CD 4 , Soluble CDS , Soluble CD 25 , Lymphopoieitic Recovery , and Endogenous Cytokines After High-Dose Chemotherapy and Blood Stem Cell Transplantation

Robert, Anthony, A. Maghazachi, 2002 .